Synthorx, a preclinical biotech developing immunotherapies for solid tumors, raised $131 million by offering 11.9 million shares at $11, the midpoint of the $10 to $12 range. The company offered additional shares to raise 31% more than anticipated. Insiders had indicated on buying up to $75 million of the IPO (57%).
Synthorx plans to list on the Nasdaq under the symbol THOR. Jefferies, Leerink Partners and Evercore ISI acted as lead managers on the deal.
